Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hong JP et al. – Mucositis of the oral cavity and pharynx is a major dose–limiting factor in the application of radiotherapy (RT) to patients with head and neck cancer. The finding suggests that rhEGF is effective and safe for the treatment of radiation–induced mucositis. Further studies are needed to determine the optimal dosage and fractionation schedule.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address